AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia
April 11, 2022 08:00 ET
|
AEON Biopharma
NEWPORT BEACH, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its...
AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel
August 11, 2021 07:05 ET
|
AEON Biopharma
NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin...
AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications
June 09, 2021 08:00 ET
|
AEON Biopharma
NEWPORT BEACH, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its...
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
April 05, 2021 08:00 ET
|
AEON Biopharma
NEWPORT BEACH, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its...
AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine
March 08, 2021 16:01 ET
|
AEON Biopharma
-Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- NEWPORT BEACH,...
AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
September 02, 2020 16:01 ET
|
AEON Biopharma
-Critical milestone transitions AEON Biopharma to clinical-stage company- -Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021- -Investment expected to provide...